Genentech’s T-DM1 Phase III: Stronger Still in Breast Cancer

With added, positive Phase III breast cancer data from a trial called EMILIA for the antibody-drug conjugate T-DM1, Roche AG subsidiary Genentech and partner ImmunoGen uplifted — but didn’t overly surprise — investors, who are waiting to see whether the first label permits front-line use in metastatic disease.
BioWorld